Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BRP-412 is an investigational small molecule therapeutic candidate developed by Bioron Pharma for the treatment of Major Depressive Disorder (MDD). According to company pipeline documentation, the drug is currently in Phase 2b clinical development. As a small molecule antidepressant candidate, BRP-412 is intended to address the unmet needs of patients suffering from MDD, a debilitating mental health condition characterized by persistent low mood, cognitive impairment, and loss of interest in daily activities. While specific details regarding its molecular target—such as neurotransmitter receptors or enzymatic pathways—have not been publicly disclosed in clinical registries or peer-reviewed literature, its progression to Phase 2b suggests it is being evaluated for efficacy, safety, and optimal dosing in patient populations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BRP-412.